A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer
A Phase 3, Randomized, Double-blind, Parallel-group, Vehicle Controlled, Multicenter Study of the Efficacy and Safety of Granexin Gel in the Treatment of Diabetic Foot Ulcer (GAIT 1)
Sponsor: Xequel Bio, Inc.
Terminated
Sponsor Decision (No safety or efficacy concerns)
This PHASE3 trial investigates Diabetic Foot Ulcers and is currently terminated or withdrawn. Xequel Bio, Inc. leads this study, which shows 16 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jul 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2022 [monthly]
Terminated PHASE3
▶ Show 11 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Mar 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2019 — Mar 2020 [monthly]
Recruiting PHASE3
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE3
-
Sep 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
Jan 2019 — Mar 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Xequel Bio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ahmedabad, India , Belagavi, India , Bhopal, India , Boucherville, Canada , Budapest, Hungary , Budziszynek, Poland , Doral, United States , Fort Worth, United States , Guwahati, India , Hialeah, United States and 15 more locations